Weight loss by dose (SURMOUNT-1, 72 weeks)
| Dose | Avg weight loss | Approx. pounds* |
|---|---|---|
| Placebo | 3.1% | ~7 lb |
| 5 mg | 15.0% | ~34 lb |
| 10 mg | 19.5% | ~41 lb |
| 15 mg | 20.9% | ~48 lb |
*Approximate, based on average trial body weight. Individual results vary. Source: SURMOUNT-1 / Zepbound labeling.
What drives your individual result
Trial averages hide wide variation. Real-world outcomes depend on the dose reached and tolerated, consistency, diet and activity, sex (men lost slightly less than women in head-to-head data), starting weight, and whether you stay on treatment. Weight tends to return if the medication is stopped, so obesity medicine is generally viewed as long-term rather than a short course.
How tirzepatide compares
Tirzepatide’s averages are among the highest for approved obesity drugs. In the head-to-head SURMOUNT-5 trial it produced 20.2% versus 13.7% for semaglutide. The newer oral GLP-1 pills land lower, around 11-14%. For the full comparison see our semaglutide vs tirzepatide and SURMOUNT-5 pages.
Setting realistic expectations
Think in ranges, not guarantees. Many people reach double-digit percentage loss; some exceed 20%, others less. The trial figures describe people who reached and held the maximum tolerated dose for 72 weeks under supervision — conditions that are hard to replicate perfectly. Pair medication with sustainable habits and clinician follow-up, and judge progress over months rather than weeks.
Maintenance matters
Losing weight is only half the story. Studies consistently show regain after stopping a GLP-1, because the underlying biology of appetite and metabolism reasserts itself. That is why obesity is increasingly treated as a chronic condition. If cost or access could interrupt treatment, plan for that with a clinician before starting, since an interrupted course can undo hard-won progress. For titration mechanics, see our dosing schedule guide.
Trial results vs real life
Clinical-trial participants are monitored closely, encouraged to adhere, and supported through titration — conditions that tend to produce better-than-average results. Real-world weight loss is often somewhat lower simply because life is messier: missed doses, dose reductions for side effects, and gaps in supply all chip away at outcomes. That is not a reason for pessimism, but it is a reason to treat the 15-21% figures as a ceiling earned under ideal conditions rather than a default you should expect automatically. The most reliable predictor of a good outcome is staying on an effective dose consistently, paired with adequate protein, activity, and clinician follow-up over many months.
Frequently asked questions
How much weight can you lose on tirzepatide?
In SURMOUNT-1, adults lost about 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks, versus about 3% on placebo.
Does a higher dose mean more weight loss?
On average, yes — results rose with dose in trials. But the highest dose is not right for everyone; tolerability and clinician guidance matter more than chasing the top dose.
How long does it take?
Meaningful weight loss typically begins within the first weeks and continues for roughly 72 weeks before tending to plateau.
Is compounded tirzepatide as effective?
The trial data come from FDA-approved tirzepatide. Compounded versions are not FDA-approved and can vary in concentration, so results are not guaranteed to match.
References
- Jastreboff AM et al. Tirzepatide once weekly for obesity (SURMOUNT-1). NEJM, 2022.
- Eli Lilly. Zepbound prescribing information.
- Weill Cornell Medicine. Head-to-head weight-loss trial (SURMOUNT-5). 2025.